Search 

Depomed, Inc. (Nasdaq:  DEPO) is a US based specialty pharmaceutical company with a focus in pain, CNS, and Women's Health.  The company has advanced three products to market and has developed a pipeline with late-stage product opportunities intended to address common medical conditions affecting large patient populations

Depomed is currently seeking US co-promotion, and Global license partners for it's marketed product Gralise (once-daily gabapentin for Post Herpetic Neuralgia), and Serada a non-hormonal treatment for Vasomotor Symptoms (menopausal hot flashes) which is currently under in registration.

Dicerna Technology: Next Generation RNAi and RNAi Delivery

Dicerna is a leading developer of RNAi drugs targeting unmet needs in cancer. The company’s novel Dicer Substrate siRNA (DsiRNA) molecules and proprietary drug delivery technologies have the demonstrated ability to silence previously undruggable disease targets. Dicerna’s RNAi platform is comprised of two key components: Dicer Substrates (DsiRNAs), which are 25-30 asymmetric double stranded RNAs that mediate RNAi with extremely high potency, and EnCore lipid nanoparticles, which are optimized for tumor delivery of RNAi molecules. The DsiRNA platform is broadly covered by the recently issued US patent 8,084,599.

Dicerna DsiRNA and Delivery Technologies enable breakthrough cancer treatments based on previously undruggable targets

Robust in vivo anti-tumor efficacy has been achieved in multiple difficult-to-treat tumors using DsiRNA Technology against classic undruggable oncology targets, both within our own pipeline and with our partner Kyowa Kirin. The company’s most advanced program targets the MYC oncogene and is focused on Hepatocellular Carcinoma (HCC), where there still remains a significant need for new treatment options. The HCC program is available for partnering.

Recent accomplishments

·         The demonstration of profound tumor responses in multiple solid tumor xenograft models.

·         The recent announcements that our partner, Kyowa Kirin, has moved the initial oncology candidate into formal development, triggering a substantial success milestone and the achievement of the in vivo efficacy milestone for the second DsiRNA oncology candidate.

·         The characterization and optimization of our EnCore lipid nanoparticle (LNP) technology and its ability to deliver DsiRNA payloads into the cell cytoplasm and achieve efficient knockdown of targeted genes.

·         The issuance of the fundamental patent covering the DsiRNA platform.

At Dicerna we can rapidly generate DsiRNA inhibitors against any gene and optimize our EnCore delivery technology to deliver to specific tumor types or organs.  We have demonstrated these capabilities in our lead HCC program, available for partnering, and can use these capabilities to develop therapeutics against targets of interest to collaborators.  I hope you have the time to meet with Dicerna during BioNetwork West to discuss our technology and areas of possible mutual interest.

EvaluatePharma®, leader in life science sector analysis, delivers exclusive commercial intelligence and analysis into industry performance globally.

With 10+ years’ experience and investment in our services, we provide meaningful, value-added information and analysis that aids in target identification, strategic decision-making, and risk mitigation aimed towards your competitive advantage and business results.

Our flexible, “one-stop” services include:
EvaluatePharma® featuring all the Deals Data you need for Business Development, Proprietary Data Standardization, Merge Company tool, Calendar of Events, Interactive NPV Analyzer, Sales by Indication and Consensus Forecasts for Marketed & Pipeline Products, plus much more to give you the most accurate view of the global market.

EP Clinical Trials simplifies complex analysis of the global clinical trials landscape including ClinicalTrials.gov, EudraCT and Japan clinical trials data source for trusted clinical intelligence you can rely on, and the time savings you need.

EvaluatePharma® Partnering Services make finding your next licensing partner easier, and features the latest assets available for partnering presented in their commercial context alongside our unique industry analysis.

EPVantage® renowned news service provides mapped commentary and analysis that keeps you abreast of the latest sector developments relevant to you.

Discover why EvaluatePharma is trusted and relied upon by life science companies big and small, the investment community and leading consultancies.

You can count on EvaluatePharma for:

• Product Forecasts to 2018
• New – Sales by Indication to 2018
• Product Deals
• M&A Transactions
• Product Historic Sales
• Clinical Trials
• Country Analysis
• Archived Historical Sales Forecasts
• Company profiles
• Drug Information
• R&D Pipelines
• Patent Risk
• News
• NPV’s of Marketed and Pipeline Products
• Calendar of Events - key events that will shape the future of the industry
• EP Vantage & Event Analyzer - analysis and commentary on key market events

Foley Hoag is a preeminent Life Sciences law firm that represents public and private clients in a wide range of transactions worldwide.  The chair of our Licensing and Strategic Alliances practice group together with one of our leading Intellectual Property partners will be available to meet with interested companies.

Fujifilm Diosynth is a leading provider of process development and cGMP manufacturing services for biopharmaceuticals. Fujifilm Diosynth offers a proven track record in process development and cGMP manufacturing of cell culture and microbial expressed proteins, vaccines, and monoclonal antibodies. The organization has facilities in Research Triangle Park, North Carolina, USA (formerly Diosynth Biotechnology) and Billingham, UK (formerly Avecia Biologics) and was acquired by Fujifilm Corporation in April 2011.  Combined, Fujifilm Diosynth brings to our clients over 25 years of experiences as a contract manufacturing organization. 

Created in 1981, Galderma is a joint venture between Nestlé and L'Oréal.

Galderma is a global leading pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology. Galderma’s important investments in R&D, extensive product portfolio, global presence and expertise in three key segments (prescription drugs, over-the-counter drugs and aesthetic and corrective solutions) contribute to maintaining its strong leadership in dermatology.

Galderma is interested in acquiring or in-licensing products for corrective dermatology and for the treatment of acne, rosacea, onychomycosis, psoriasis, seborrheic dermatitis, atopic dermatitis, other inflammatory dermatoses, non-melanoma skin cancer, viral warts, and pigmentary disorders.